Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RA mutant melanoma...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Journal of Skin Cancer |
| Online Access: | http://dx.doi.org/10.1155/2013/735282 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545409030946816 |
|---|---|
| author | Farid Menaa |
| author_facet | Farid Menaa |
| author_sort | Farid Menaa |
| collection | DOAJ |
| description | Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RA mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, the newly-approved immunotherapeutic, ipilimumab, produces durable responses in patients presenting CTLA-4 T-cell surface protein. Nevertheless, the possible synergy in combining these two therapeutic strategies primarily rely on the rational design of medical protocols (e.g., sequence and timing of agent administration; drug selectivity; compatibility of combined therapies i.e., adoptive T cell or agents, i.e., MEK inhibitor trametinib, PD-1 and PDL-1 blockers). Improved therapeutic protocols shall overcome therapeutic limitations such as the (i) tolerability and safety (i.e., minimal toxic side-effects); (ii) progression free survival (e.g., reduced relapse disease frequency); (iii) duration response (i.e., decreased drug resistance). Eventually, multidisciplinary approaches are still requested (e.g., genomics for personalized medicine, nanomedicine to overcome low free-drug bioavailability and targeting, systematic search of “melanoma stem cells” to enhance the prognosis and develop more valuable theranostics). In this paper, I will mainly present and discuss the latest and promising treatments for advanced cutaneous melanomas. |
| format | Article |
| id | doaj-art-ee41b24ab60e4236806eb7c23f7d1e6b |
| institution | Kabale University |
| issn | 2090-2905 2090-2913 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Skin Cancer |
| spelling | doaj-art-ee41b24ab60e4236806eb7c23f7d1e6b2025-02-03T07:26:05ZengWileyJournal of Skin Cancer2090-29052090-29132013-01-01201310.1155/2013/735282735282Latest Approved Therapies for Metastatic Melanoma: What Comes Next?Farid Menaa0Department of Oncology, Stem Cells and Nanomedicine, Fluorotronics, Inc., 2453 Cades Way, Building C, San Diego, CA 92081, USANowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RA mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, the newly-approved immunotherapeutic, ipilimumab, produces durable responses in patients presenting CTLA-4 T-cell surface protein. Nevertheless, the possible synergy in combining these two therapeutic strategies primarily rely on the rational design of medical protocols (e.g., sequence and timing of agent administration; drug selectivity; compatibility of combined therapies i.e., adoptive T cell or agents, i.e., MEK inhibitor trametinib, PD-1 and PDL-1 blockers). Improved therapeutic protocols shall overcome therapeutic limitations such as the (i) tolerability and safety (i.e., minimal toxic side-effects); (ii) progression free survival (e.g., reduced relapse disease frequency); (iii) duration response (i.e., decreased drug resistance). Eventually, multidisciplinary approaches are still requested (e.g., genomics for personalized medicine, nanomedicine to overcome low free-drug bioavailability and targeting, systematic search of “melanoma stem cells” to enhance the prognosis and develop more valuable theranostics). In this paper, I will mainly present and discuss the latest and promising treatments for advanced cutaneous melanomas.http://dx.doi.org/10.1155/2013/735282 |
| spellingShingle | Farid Menaa Latest Approved Therapies for Metastatic Melanoma: What Comes Next? Journal of Skin Cancer |
| title | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
| title_full | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
| title_fullStr | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
| title_full_unstemmed | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
| title_short | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
| title_sort | latest approved therapies for metastatic melanoma what comes next |
| url | http://dx.doi.org/10.1155/2013/735282 |
| work_keys_str_mv | AT faridmenaa latestapprovedtherapiesformetastaticmelanomawhatcomesnext |